P21 / P021 Peptide

ID: p21_peptide

Aliases: P21, P021, Peptide 021, neurotrophic adamantane peptide

Type: compound

Route/form: preclinical/research peptide; no approved human route

Status: research

Evidence level: preclinical

Best data tier: non-human experimental

Support scope: non-human/mechanistic, review/regulatory

Source types: preclinical, regulatory_safety

Linked sources: 3

Broad outcomes: Brain / mood / sleep

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• CNTF-derived neurotrophic-peptide hypothesis
• BDNF/neurogenesis/synaptogenesis pathways
• tau/amyloid model endpoints

Optimization domains

• brain
• nootropic
• neuroprotection
• alzheimers model

Research basis

• Preclinical work on P021/P21-style neurotrophic adamantane peptides gives a plausible cognitive/neurodegeneration-model rationale.

Limits, risks, and missing evidence

• No mature human efficacy data found.
• Animal Alzheimer-model and learning endpoints should be strongly down-ranked for healthy cognition claims.

Risk flags

• preclinical only
• unapproved context
• neuroactive
• identity uncertain

Linked papers, labels, and reviews

1. Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptogenesis, and inhibit amyloid beta-associated neuronal death
   preclinical / sciencedirect_p021_adamantane_2010
   Indirect mechanistic anchor for Adamax-style Semax/P021/adapted peptide claims; not direct Adamax efficacy evidence.
2. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease
   preclinical / pubmed_p21_ad_model_2017
   P21/P021 preclinical Alzheimer-model anchor; no approved or mature human data.
3. Medsafe Medicines Classification Committee: classification of unscheduled peptides including Adamax and P21
   regulatory_safety / medsafe_unscheduled_peptides_2025
   Regulatory classification context for nootropic/research peptides with limited direct clinical evidence.